Emerging immunotargets and immunotherapies in prostate cancer

Rodolfo Montironi, Matteo Santoni, Valeria Sotte, Liang Cheng, Antonio Lopez-Beltran, Francesco Massari, Marc R. Matrana, Holger Moch, Rossana Berardi, Marina Scarpelli

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Innate and adaptive immunity are both involved in prostate cancer (PCa) carcinogenesis and progression. On this scenario, several immunotherapeutic approaches have been proposed and are presently under extensive investigation in PCa patients. Among emerging immune targets, immune checkpoint inhibitors such as anti-cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), anti-Programmed death-1 (PD-1) and anti-Programmed death-ligand-1 (PD-L1) agents seem to represent the most promising candidate for these patients, together with oncolytic viruses and vaccines, used alone or in combined strategies. In this review, we focused on emerging immunotherapeutic approaches in patients with PCa, showing the rational for their association with current standard therapies including anti-androgen agents, chemo-or radiation therapy.

Original languageEnglish (US)
Pages (from-to)777-782
Number of pages6
JournalCurrent Drug Targets
Volume17
Issue number7
StatePublished - Jun 1 2016

Fingerprint

Immunotherapy
Prostatic Neoplasms
Chemotherapy
Radiotherapy
Viruses
Oncolytic Viruses
Androgens
Vaccines
Adaptive Immunity
Ligands
Innate Immunity
Carcinogenesis
Proteins
Therapeutics
Thomsen-Friedenreich antibodies

Keywords

  • Immunotherapy
  • Prognosis
  • Programmed death-1
  • Prostate cancer
  • Vaccines

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Montironi, R., Santoni, M., Sotte, V., Cheng, L., Lopez-Beltran, A., Massari, F., ... Scarpelli, M. (2016). Emerging immunotargets and immunotherapies in prostate cancer. Current Drug Targets, 17(7), 777-782.

Emerging immunotargets and immunotherapies in prostate cancer. / Montironi, Rodolfo; Santoni, Matteo; Sotte, Valeria; Cheng, Liang; Lopez-Beltran, Antonio; Massari, Francesco; Matrana, Marc R.; Moch, Holger; Berardi, Rossana; Scarpelli, Marina.

In: Current Drug Targets, Vol. 17, No. 7, 01.06.2016, p. 777-782.

Research output: Contribution to journalArticle

Montironi, R, Santoni, M, Sotte, V, Cheng, L, Lopez-Beltran, A, Massari, F, Matrana, MR, Moch, H, Berardi, R & Scarpelli, M 2016, 'Emerging immunotargets and immunotherapies in prostate cancer', Current Drug Targets, vol. 17, no. 7, pp. 777-782.
Montironi R, Santoni M, Sotte V, Cheng L, Lopez-Beltran A, Massari F et al. Emerging immunotargets and immunotherapies in prostate cancer. Current Drug Targets. 2016 Jun 1;17(7):777-782.
Montironi, Rodolfo ; Santoni, Matteo ; Sotte, Valeria ; Cheng, Liang ; Lopez-Beltran, Antonio ; Massari, Francesco ; Matrana, Marc R. ; Moch, Holger ; Berardi, Rossana ; Scarpelli, Marina. / Emerging immunotargets and immunotherapies in prostate cancer. In: Current Drug Targets. 2016 ; Vol. 17, No. 7. pp. 777-782.
@article{eac260f021004c3b876a1d78e90ec72b,
title = "Emerging immunotargets and immunotherapies in prostate cancer",
abstract = "Innate and adaptive immunity are both involved in prostate cancer (PCa) carcinogenesis and progression. On this scenario, several immunotherapeutic approaches have been proposed and are presently under extensive investigation in PCa patients. Among emerging immune targets, immune checkpoint inhibitors such as anti-cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), anti-Programmed death-1 (PD-1) and anti-Programmed death-ligand-1 (PD-L1) agents seem to represent the most promising candidate for these patients, together with oncolytic viruses and vaccines, used alone or in combined strategies. In this review, we focused on emerging immunotherapeutic approaches in patients with PCa, showing the rational for their association with current standard therapies including anti-androgen agents, chemo-or radiation therapy.",
keywords = "Immunotherapy, Prognosis, Programmed death-1, Prostate cancer, Vaccines",
author = "Rodolfo Montironi and Matteo Santoni and Valeria Sotte and Liang Cheng and Antonio Lopez-Beltran and Francesco Massari and Matrana, {Marc R.} and Holger Moch and Rossana Berardi and Marina Scarpelli",
year = "2016",
month = "6",
day = "1",
language = "English (US)",
volume = "17",
pages = "777--782",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Emerging immunotargets and immunotherapies in prostate cancer

AU - Montironi, Rodolfo

AU - Santoni, Matteo

AU - Sotte, Valeria

AU - Cheng, Liang

AU - Lopez-Beltran, Antonio

AU - Massari, Francesco

AU - Matrana, Marc R.

AU - Moch, Holger

AU - Berardi, Rossana

AU - Scarpelli, Marina

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Innate and adaptive immunity are both involved in prostate cancer (PCa) carcinogenesis and progression. On this scenario, several immunotherapeutic approaches have been proposed and are presently under extensive investigation in PCa patients. Among emerging immune targets, immune checkpoint inhibitors such as anti-cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), anti-Programmed death-1 (PD-1) and anti-Programmed death-ligand-1 (PD-L1) agents seem to represent the most promising candidate for these patients, together with oncolytic viruses and vaccines, used alone or in combined strategies. In this review, we focused on emerging immunotherapeutic approaches in patients with PCa, showing the rational for their association with current standard therapies including anti-androgen agents, chemo-or radiation therapy.

AB - Innate and adaptive immunity are both involved in prostate cancer (PCa) carcinogenesis and progression. On this scenario, several immunotherapeutic approaches have been proposed and are presently under extensive investigation in PCa patients. Among emerging immune targets, immune checkpoint inhibitors such as anti-cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), anti-Programmed death-1 (PD-1) and anti-Programmed death-ligand-1 (PD-L1) agents seem to represent the most promising candidate for these patients, together with oncolytic viruses and vaccines, used alone or in combined strategies. In this review, we focused on emerging immunotherapeutic approaches in patients with PCa, showing the rational for their association with current standard therapies including anti-androgen agents, chemo-or radiation therapy.

KW - Immunotherapy

KW - Prognosis

KW - Programmed death-1

KW - Prostate cancer

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84964207200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964207200&partnerID=8YFLogxK

M3 - Article

C2 - 26898309

AN - SCOPUS:84964207200

VL - 17

SP - 777

EP - 782

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 7

ER -